George A Fisher
Stanford University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name George A Fisher as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:47 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03196232 · Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric CancerGeorge Albert Fisher · completed · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma · principal investigator
- Ph1NCT01769222 · Ipilimumab and Local Radiation for Selected Solid TumorsStanford University · terminated · Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma · principal investigator
- Ph2NCT00404066 · Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast CancerGeorge Albert Fisher · completed · Breast Cancer, Metastatic Breast Cancer · principal investigator
- Ph2NCT00403130 · Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast CancerGeorge Albert Fisher · completed · Breast Cancer, Metastatic Breast Cancer · principal investigator
- Ph1/Ph2NCT00226941 · A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal CancerGeorge Albert Fisher · terminated · Rectal Cancer, Colo-rectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- CLINICAL TRIAL: RADIATION THERAPY FOLLOWED BY SURGICAL RESECTION FOR RECTAL CANCM01RR000070 · NCRR · STANFORD UNIVERSITY · fiscal years 1998 to 2008 · $4,665 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:47 UTC. The ranking covers the 200 most relevant of 52 PubMed records, and a shared surname and initials can bring in a namesake. All 52 on PubMed
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.N Engl J Med · 20157,784 citationsRCR 243.1
- 5,520 citationsRCR 184.9
- First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.J Clin Oncol · 2019542 citationsRCR 18.2
- Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.Proc Natl Acad Sci U S A · 2001442 citationsRCR 7.6
- 409 citationsRCR 15.1
- Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).J Clin Oncol · 2023290 citationsRCR 36.6
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.J Immunother Cancer · 2017283 citationsRCR 8.5
- Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys · 2008269 citationsRCR 7.0
- Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys · 2005252 citationsRCR 6.5
- Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.Int J Radiat Oncol Biol Phys · 2010230 citationsRCR 6.3